United Health (UNH) Offering Possible 16.82% Return Over the Next 8 Calendar Days

United Health's most recent trend suggests a bullish bias. One trading opportunity on United Health is a Bull Put Spread using a strike $217.50 short put and a strike $212.50 long put offers a potential 16.82% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $217.50 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $4.28 would be incurred if the stock dropped below the $212.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for United Health is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for United Health is bullish.

The RSI indicator is at 63.15 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for United Health

UnitedHealth's MedExpress partners with Walgreens on urgent care
Tue, 05 Dec 2017 21:15:12 +0000
A clinic chain owned by UnitedHealh Group Inc.’s Optum unit has partnered with Walgreens Boots Alliance Inc. to open urgent care centers that will be connected to Walgreens' in-store clinics. Walgreens Chief Marketing Officer Adam Holyk offered some details about the partnership with Optum's MedExpress in an interview with CNBC on Monday, when the retailer announced a broader revamp of its stores . MedExpress also announced in May it would open three “neighborhood medical centers” adjacent to Walgreens locations in the Twin Cities.

U.S. health care is changing in a big way. The CVS-Aetna deal shows how
Tue, 05 Dec 2017 19:27:28 +0000
Standalone pharmacy-benefit managers negotiate drug prices and have long been a feature of America’s health care system. But that may not be true for much longer.

Multiple Companies Reach Yearly Highs
Tue, 05 Dec 2017 16:09:39 +0000
Five companies have each managed to achieve 52-week highs as of late

How an Aetna/CVS behemoth would stack up against UnitedHealth
Tue, 05 Dec 2017 16:00:20 +0000
CVS Health Corp.’s $69 billion deal to acquire Aetna is arguably more a response to threats posed by UnitedHealth Group Inc. than a reaction to Amazon.com Inc.’s murky plans for entering the health care market. Measured by annual revenue, a combined CVS and Aetna would be larger than UnitedHealth (UNH). If the deal closes, CVS would generate about $240 billion in revenue, while UnitedHealth projects between $223 billion and $225 billion for 2018.

Forget Amazon. Health Companies Really Want to Be UnitedHealth
Mon, 04 Dec 2017 18:31:15 +0000
As the specter of Amazon.com Inc. looms over the health-care industry, it’s easy to see the tech giant’s threat as a major factor behind the megadeal between CVS Health Corp. and Aetna Inc.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.